“It was a science fiction and now it's reality,” said Professor Polina Stepensky, director of Hadassah’s bone marrow transplantation and immunotherapy department.
Stepensky developed the treatment alongside Cyril Cohen, head of Bar Ilan University’s cancer immunology and immunotherapy laboratory.
“We know that we are unable to cure myeloma, but we are able to switch it into a chronic disease,” she said.
“When I graduated medical school in 1998, survival with myeloma was two years and now it is more than 10, and we hope to increase it even more. Now patients with diabetes live a normal life, so I hope the same for those with myeloma.”
The trials - part of a clinical study approved by the Helsinki Committee and the Israeli Ministry of Health - are now in their second phase, but a patent license has been acquired by a pharmaceutical company in the US, where a separate clinical trial will soon begin.
Stepensky hopes the treatment will be approved by the US Food and Drug Administration within a year. There are also clinical trials for a separate CART-T treatment underway in the UK, at University College Hospital.
Ali Rismani, a consultant haematologist at the hospital said that while the treatment is not effective for everyone, and is unsuitable for very elderly and unfit people, the results of the trials are “promising”.
“CAR-T gives us a treatment option for patients who've run out of treatments...It's not a straightforward procedure but if it does work, and depending on which CAR-T is used, [patients can live for] an extra couple of years, sometimes more,” Rismani said.
Dr Rupal Mistry, a spokeswoman for Cancer Research UK, said: “Results from this ongoing early-stage study using CAR-T cell therapy are encouraging for people with advanced multiple myeloma. While more work is needed to confirm these exciting findings on a wider scale, this research is bringing us one step closer to being able to provide more effective treatment options for people with this disease.”
